Search
Fidaxomicin
go.drugbank.com/drugs/DB08874ApprovedInvestigational[A7445] It mediates its potent bactericidal action on the bacteria by inhibiting the bacterial RNA synthase, thereby disrupting bacterial transcription. … [A190486] The approved indication of fidaxomicin was expanded by the FDA in January 2020 to include pediatric patients over the age of 6 months in the treatment population.[L11575]
Albiglutide
go.drugbank.com/drugs/DB09043ApprovedInvestigationalWithdrawnAlbiglutide was approved on April 15, 2014 by the FDA. … It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin.
Clidinium
go.drugbank.com/drugs/DB00771ApprovedClidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. … It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.
Synonyms: N-methyl quinuclidinyl benzilateMixtures: Nu-chlorax Capsules USPClopidogrel
go.drugbank.com/drugs/DB00758ApprovedInvestigational[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and … [A180547] Clopidogrel was granted FDA approval on 17 November 1997.[L7213]
Mixtures: CO-DEGREGANIvosidenib
go.drugbank.com/drugs/DB14568ApprovedInvestigational[L46287] It was fully approved by the EMA in May 2023.[L46596] … [A248745] Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults.
Liraglutide
go.drugbank.com/drugs/DB06655ApprovedInvestigational[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. … [A6932] Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor.
Synonyms: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37], N²⁶-(N-Hexadecanoyl-L-gamma-glutamyl)-[34-L-arginine]glucagon-like peptide 1-(7-37)-peptidePalbociclib
go.drugbank.com/drugs/DB09073ApprovedInvestigational[A176810] Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth. … [L5867] It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male
Brexucabtagene autoleucel
go.drugbank.com/drugs/DB15699ApprovedInvestigational[L15148] Brexucabtagene autoleucel was granted full approval by the FDA on July 24, 2020 for the treatment of MCL and acute lymphoblastic leukemia (ALL), and is currently available through Kite Pharma … Mantle cell lymphoma (MCL) is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant.
Sinapultide
go.drugbank.com/drugs/DB11332ApprovedWithdrawnThis large disadvantage was overcome with animal-derived surfactant products which contain specific proteins but are limited, but must be derived from animal sources. … [L2506] The product was originally developed by the Scripps Research Institute, then licensed to Windtree Therapeutics.
Asparagine
go.drugbank.com/drugs/DB00174ApprovedNutraceuticalWithdrawnA non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from aspartic acid and ammonia by asparagine synthetase.
Mixtures: The Classeum Co., Ltd., The Classeum Co., Ltd.